Danvatirsen
- Generic Name
- Danvatirsen
- Drug Type
- Biotech
- CAS Number
- 1402357-06-5
- Unique Ingredient Identifier
- 31N550RD05
- Background
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
Phase 2
Terminated
- Conditions
- AscitesGastrointestinal NeoplasmsOvarian CancerOvarian NeoplasmsGastrointestinal Cancer
- Interventions
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT02417753
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma MetastaticAdvanced Adult Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT01839604
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01563302
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath